Company intelligence / Profile preview
Adienne
Lugano, Ticino, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
Adienne markets TEPADINA® (thiotepa) and phelinun (melphalan) for orphan and hematological indications, with clinical and preclinical pipeline drugs in immunological and hematological diseases; its monoclonal antibody for aGvHD is at the investigational stage[2][5][6].
- Therapeutic areas
- HematologyRare DiseasesImmunology
- Modalities
- Small moleculeMonoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Russian Direct Investment Fund (RDIF) (for manufacturing agreement on Sputnik V vaccine)
Beyond the preview
Go deeper on Adienne.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adienne.